Sign in

You're signed outSign in or to get full access.

Gregory Wasson

Director at OptimizeRx
Board

About Gregory Wasson

Independent director since July 2020; age 66. Former President and CEO of Walgreens (2009–2015) and Walgreens Boots Alliance, Inc. (2015), now President and Co‑founder of Wasson Enterprise (since 2016). He served as Executive Chairman of Innovation Associates (iA) from November 2019 to December 2024 and is Chairman and co‑founder of Cooler Screens (since 2017). Current public company directorship: P3 Health Partners Inc.; prior boards include PNC Financial Services Group (2015–2018) and Verizon Communications (2013–2018) .

Past Roles

OrganizationRoleTenureCommittees/Impact
WalgreensPresident & CEO2009–2015Led large-scale retail operations and healthcare strategy
Walgreens Boots Alliance, Inc.President & CEO2015Oversaw integration and leadership of combined enterprise
WalgreensPresident & COO2007–2009Senior operating leadership
Walgreen Health ServicesPresident & EVP2001–2006Healthcare services leadership
WalgreensVP Store Operations1999–2001Retail operations management
WalgreensDistrict Manager1986–1999Field leadership
WalgreensPharmacy Technician, Pharmacist, Store Manager1981–1986Early-career pharmacy and store leadership

External Roles

OrganizationRoleTenureNotes
Wasson EnterprisePresident & Co‑founder2016–presentFamily office building high‑growth businesses
Innovation Associates (iA)Executive Chairman2019–2024Pharmacy automation leader
Cooler Screens, Inc.Co‑founder & Chairman2017–presentRetail media platform at point of sale
P3 Health Partners Inc.DirectorcurrentPublic, population health management
Foresight Acquisition Corp.Chairperson2020–2021SPAC predecessor to P3; governance leadership
Reliefband; Performance Health SystemsDirectorcurrentPrivately held companies
PNC Financial Services GroupDirector2015–2018Prior public board
Verizon CommunicationsDirector2013–2018Prior public board

Board Governance

  • Independence: Board determined all current directors (including Wasson) are independent under Nasdaq; committees composed entirely of independent directors .
  • Chairperson: Independent chair (Lynn O’Connor Vos) and independent director executive sessions occur regularly .
  • Attendance: In 2024, Board held 16 meetings; each incumbent director attended at least 75% of board and committee meetings; all directors attended last year’s annual meeting .
CommitteeRole (Wasson)2024 MeetingsNotes
Compensation CommitteeMember3Chair: James Lang; remit includes CEO pay, executive pay, plans, clawback, ownership guidelines
Audit CommitteeNot a member12Chair: Patrick Spangler; responsibilities include auditor oversight, financial reporting, cyber risk, related party reviews
Nominating & Governance CommitteeNot a member3Chair: Catherine Klema; board composition, ESG oversight, governance guidelines

Fixed Compensation

ComponentAmount ($)Notes
Fees Earned or Paid in Cash (2024)45,000 Actual cash received for 2024
Program – Annual Cash Retainer40,000 Standard cash retainer for non‑employee directors
Program – Compensation Committee Member5,000 Incremental annual retainer per Compensation Committee member
Program – Chair fees (not applicable to Wasson)10,000 (Comp Chair); 20,000 (Audit Chair); 8,000 (N&G Chair) For chair roles; Wasson is not a chair

Performance Compensation

Equity AwardGrant Date Value ($)Units/StatusVesting
Annual RSU grant (2024)149,999 RSUs; number not disclosed in tableNot disclosed
Unvested RSUs (as of 12/31/2024)13,286 units Time‑based RSUs outstanding
Ownership Guidelines – Directors3x annual cash retainer; retention of 50% of net shares until compliant Must comply within 5 years of election or 6/22/2021

Compensation mix signal: Equity comprised ~77% of Wasson’s 2024 director pay ($149,999 equity vs. $45,000 cash), aligning incentives with shareholders .

Other Directorships & Interlocks

CompanyRoleTenurePotential Interlock/Conflict
P3 Health Partners Inc.DirectorcurrentNo related‑party transactions disclosed by OPRX; independence affirmed
Cooler Screens, Reliefband, Performance Health SystemsDirector/ChaircurrentPrivate companies; no OPRX related‑party exposure disclosed
PNC Financial Services Group; Verizon CommunicationsDirector (prior)2013–2018; 2015–2018Prior roles; no current interlocks

Expertise & Qualifications

  • Board skill matrix indicates Wasson contributes capabilities in risk management, healthcare industry, digital healthcare technology, other public company board experience, corporate governance, executive compensation, and human capital management .

Equity Ownership

HolderShares Beneficially OwnedPercent of OutstandingNotes
Gregory Wasson47,315 <1% Includes 13,286 RSUs vesting within 60 days of record date; shares outstanding were 18,493,447

Insider Trades (Form 4)

Filing DateTransaction DateTypeSharesNotes/Link
2024-06-112024-06-05RSU grant (one‑for‑one)N/ASEC Form 4 indicates RSU grant; earliest transaction date 06/05/2024
2025-06-122025-06-11RSU grantN/ACompany site lists Wasson Form 4 filing (PDF)

Related Party Transactions and Conflicts

  • Audit Committee reviews related party transactions; Board’s independence review found no transactions or relationships that would compromise independence for Wasson .
  • Corporate policies prohibit short sales, hedging, margin accounts, and pledging, reducing alignment risk .

Governance Assessment

  • Strengths: Independent director; equity‑heavy director pay; compliance with director stock ownership guidelines or time remaining to comply; strong board governance practices (independent chair; executive sessions; overboarding limits) .
  • Engagement: Attended ≥75% of Board/committee meetings in 2024; Board met 16 times; his committee met 3 times; attended last annual meeting .
  • RED FLAGS: SEC administrative order (Walgreens, 2018) resolved with Wasson agreeing to a $160,000 civil penalty and cease‑and‑desist; while historical and unrelated to OPRX operations, it is a governance blemish to monitor for disclosure and potential investor perception impact .
  • Compensation Committee role: As member, influences CEO and executive pay, clawback, ownership guidelines, and succession planning; Compensation Committee uses independent consultant (Pearl Meyer) and assessed consultant independence, which supports governance quality .

Overall, Wasson brings deep healthcare retail and operational experience, public board seasoning, and alignment via equity grants. Independence and attendance are satisfactory, with no OPRX related‑party issues disclosed; continued transparency around past SEC matter and adherence to anti‑hedging/pledging policies mitigate governance concerns .